Application of read-across to data-poor N-nitrosamines: N-nitroso-ulifloxacin, a case study
Open Access
- 7 June 2026
- journal article
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 171, 106155
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA)Regulatory Toxicology and Pharmacology, 2024
- Nitrosamine acceptable intakes should consider variation in molecular weight: The implication of stoichiometric DNA damageRegulatory Toxicology and Pharmacology, 2023
- The Landscape of Potential Small and Drug Substance Related Nitrosamines in PharmaceuticalsJournal of Pharmaceutical Sciences, 2022
- Genetic toxicology in silico protocolRegulatory Toxicology and Pharmacology, 2019
- Assessing uncertainty in read-across: Questions to evaluate toxicity predictions based on knowledge gained from case studiesComputational Toxicology, 2019
- Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infectionsInternational Journal of Antimicrobial Agents, 2011
- An evaluation of the sensitivity of the Ames assay to discern low-level mutagenic impuritiesRegulatory Toxicology and Pharmacology, 2007
- A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicityRegulatory Toxicology and Pharmacology, 2006
- Structure-activity relations in carcinogenesis by N-nitroso compoundsCancer and Metastasis Reviews, 1987
- N-nitrosamines: bacterial mutagenesis and in vitro metabolismMutation Research/Reviews in Genetic Toxicology, 1987